TrialJCO precision oncology2024

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

Jun Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.